– UK, London – IXICO plc (Ticker: IXI), the brain health company, today announces the following changes to the Board, all of which take immediate effect:
Mark will join the Remuneration Committee which is chaired by Tim Sharpington and the Audit Committee which is chaired by John Bradshaw.
David Brister, who joined the Board following the acquisition of Optimal Medicine Limited, stepped down as a Non-Executive Director having helped oversee the successful integration of this acquisition.
Derek Hill, Chief Executive Officer of IXICO, said: “We are grateful to Andy Richards for the huge contribution he has made to IXICO. He set the vision for IXICO’s development into a digital healthcare company for brain health, identifying the opportunities to raise growth capital through admission onto AIM in 2013, and the acquisition of Optimal Medicine in 2015.”
Mark Warne, Non-Executive Director of IXICO and Head of Healthcare at IP Group plc, said: “I am excited to be joining the board of IXICO and I see significant potential for it to lead in the CNS and behavioural health fields in the rapidly growing digital health market. Its team is highly respected by industry and government for its brain health specialisation and the Company has some fantastic technologies. I would also like to take this opportunity to thank David Brister for his recent contribution to IXICO and prior contribution as Chairman at Optimal Medicine where IP Group was a shareholder”.
IXICO’s innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.
The Company’s brain health focus includes Alzheimer’s disease, Huntington’s disease, multiple sclerosis, behavioural health, child and adolescent mental health.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.